



editors:

Alex A. Adjei

John K. Buolamwini

# Novel Anticancer Agents

strategies  
for discovery and  
clinical testing



# **Novel Anticancer Agents**

**Strategies for Discovery  
and Clinical Testing**

This Page Intentionally Left Blank

# **Novel Anticancer Agents**

## **Strategies for Discovery and Clinical Testing**

Editors

**Alex A. Adjei**

Mayo Clinic and Foundation  
Rochester, Minnesota

**John K. Buolamwini**

College of Pharmacy  
University of Tennessee Health Science Center  
Memphis, Tennessee




AMSTERDAM • BOSTON • HEIDELBERG • LONDON  
NEW YORK • OXFORD • PARIS • SAN DIEGO  
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier  
30 Corporate Drive, Suite 400, Burlington, MA 01803, USA  
525 B Street, Suite 1900, San Diego, California 92101-4495, USA  
84 Theobald's Road, London WC1X 8RR, UK

This book is printed on acid-free paper. 

Copyright © 2006, Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, E-mail: [permissions@elsevier.com](mailto:permissions@elsevier.com). You may also complete your request on-line via the Elsevier homepage (<http://elsevier.com>), by selecting "Support & Contact" then "Copyright and Permission" and then "Obtaining Permissions."

**Library of Congress Cataloging-in-Publication Data**  
Application submitted

**British Library Cataloguing-in-Publication Data**  
A catalogue record for this book is available from the British Library.

ISBN 13: 978-0-12-088561-9

ISBN 10: 0-12-088561-1

For information on all Elsevier Academic Press publications  
visit our Web site at [www.books.elsevier.com](http://www.books.elsevier.com)

Printed in the United States of America

05 06 07 08 09 10 9 8 7 6 5 4 3 2 1

Working together to grow  
libraries in developing countries

[www.elsevier.com](http://www.elsevier.com) | [www.bookaid.org](http://www.bookaid.org) | [www.sabre.org](http://www.sabre.org)

ELSEVIER

BOOK AID  
International

Sabre Foundation

# **CONTENTS**

**CONTRIBUTORS XI**

**PREFACE XV**

## **I STRATEGIES FOR DRUG DISCOVERY**

### **I A Survey of Novel Molecular Targets for Anticancer Drug Discovery**

JOHN K. BUOLAMWINI

- I. Introduction 1
- II. Overview of Growth Factor Induced Mitogenic Signaling 3
- III. Protein Kinases and Phosphatases 4
- IV. Adapter Proteins 12
- V. GTP-Binding Proteins 12
- VI. Oncogenic Transcription Factors 13
- VII. Apoptosis, Cell Survival, and Life Span Targets 15
- VIII. Angiogenesis and Metastasis Molecular Factors 17
- IX. Protein Degradation and Chaperoning Targets 19
- X. Chromatin Remodeling Factors 19
- XI. Conclusion 20
- References 20

## **2 Microarrays: Small Spots Produce Major Advances in Pharmacogenomics**

M. NEES, W. KUSNEZOW, AND C. D. WOODWORTH

- I. Introduction to Microarrays 38
- II. Advantages of DNA Microarrays 44
- III. Major DNA Array Formats: Something for Everyone 45
- IV. What is the Best Way to Interface with Microarrays? 52
- V. Microarrays and Pharmacogenomics: Revolutionizing Discovery of New Drugs and Gene Function 55
- VI. What Can Go Wrong in cDNA Microarray Experimentation? 65
- VII. Array-Based Proteomics: How to Investigate Protein Complexity 68
- VIII. Emerging Microarray Technologies for High-Throughput Proteome Investigation: A Technical Overview 68
- IX. Current and Future Applications of Protein Arrays in Drug Discovery 71
- X. How to Deal with all that Data 73
- XI. The Future is Only Going to Get Better 74
- References 76

## **3 Strategies to Target Chemotherapeutics to Tumors**

CHARLES F. ALBRIGHT AND PEARL S. HUANG

- I. Background and Rationale 83
- II. Antibody-Directed Enzyme Prodrug Technique 84
- III. Passive Tumor Targeting 84
- IV. Targeting by Binding to Tumor Cell Surface Molecules 85
- V. Enzyme-Activated Targeting 85
- VI. Summary and Future Directions 90
- References 90

## **4 QSAR and Pharmacophore Mapping Strategies in Novel Anticancer Drug Discovery**

JAMES J. KAMINSKI

- I. Introduction 93
- II. Pharmacophore Definition 94
- III. Pharmacophore Validation 99
- IV. Conclusions 104
- References 104

## **5 Applications of Nuclear Magnetic Resonance and Mass Spectrometry to Anticancer Drug Discovery**

ROBERT POWERS AND MARSHALL M. SIEGEL

- I. Introduction 107
- II. NMR in Anticancer Drug Discovery 109
- III. Mass Spectrometry in Anticancer Drug Discovery 140

- IV. MS/NMR Screening Assay 162
- V. Conclusions 172
- Acknowledgements 172
- References 173

## **6 Antisense Strategies for the Development of Novel Cancer Therapeutics**

RUIWEN ZHANG AND HUI WANG

- I. Introduction 191
- II. Design and Evaluation of Antisense Oligonucleotides 193
- III. Conclusion 202
- Acknowledgements 203
- References 203

## **7 Antibodies and Vaccines as Novel Cancer Therapeutics**

SVETOMIR N. MARKOVIC AND ESTEBAN CELIS

- I. Introduction 207
- II. Anti-Tumor Antibodies 207
- III. Cancer Vaccines 212
- IV. Conclusion 218
- References 219

## **8 Inhibitors of Apoptosis as Targets for Cancer Therapy**

M. SAEED SHEIKH AND YING HUANG

- I. The Inhibitors of Apoptosis 223
- II. Concluding Remarks 229
- References 230

## **9 Preclinical Testing and Validation of Novel Anticancer Agents**

LLOYD R. KELLAND

- I. Introduction 233
- II. Target Validation 234
- III. A Generic Cascade for Anticancer Drug Discovery 235
- IV. High-Throughput Cell-Free Screens for Activity Against the Target 237
- V. *In Vitro* Cell Line Models 238
- VI. *In Vivo* Testing of Novel Compounds 240
- VII. Cassette-Dosing 240
- VIII. Pharmaceutical Considerations 241
- IX. High-Throughput *In Vivo* Anti-Tumor Testing: The Hollow Fiber Assay 241
- X. Human Tumor Xenografts 242
- XI. Orthotopic, Transgenic, and Other Animal Models 243



- XII. Pharmacodynamics 244
- XIII. Summary 245
  - Acknowledgements 245
  - References 245

## **II METHODS FOR CLINICAL TESTING OF NOVEL AGENTS**

### **10 Surrogate End Points and Biomarkers for Early Trials of Novel Anticancer Agents**

ALEX A. ADJEI

- I. Introduction 249
- II. What are Targeted Agents? 250
- III. Surrogate Markers or Biomarkers? 250
- IV. Biomarkers as Indicators of Drug Effect *In Vivo* 252
- V. Biomarkers as Predictive Factors 252
- VI. Biomarkers as Prognostic Factors 253
- VII. Technical Issues in the Evaluation of Drug Effects *In Vivo* 254
- VIII. Lessons for the Future 261
  - Acknowledgements 261
  - References 261

### **11 Regulatory Considerations in Clinical Trials of Novel Anticancer Drugs**

GRANT WILLIAMS AND RICHARD PAZDUR

- I. Introduction 263
- II. Overview of Cancer Drug Regulation 264
- III. Regulatory Considerations in Early Cancer Drug Development 267
- IV. Regulatory Considerations in Late Drug Development 271
- V. Conclusion 283
  - Acknowledgements 283
  - References 283

### **12 Improving the Efficacy and Safety of Anticancer Agents—The Role of Pharmacogenetics**

MARGARET-MARY AMEYAW AND HOWARD L. MCLEOD

- I. Introduction 286
- II. Thiopurine Methyltransferase 286
- III. DPD 288
- IV. Thymidylate Synthase 289
- V. ABC Family of Drug Transporters 291

- VI. UDP-Glucuronosyltransferase IAI Pharmacogenetics and Irinotecan 292
- VII. MTHFR Reductase Pharmacogenetics 293
- VIII. Cytochrome P4503A Pharmacogenetics 293
- IX. Conclusion 293
  - Acknowledgements 294
  - References 294

### **13 Imaging of Pharmacodynamic End Points in Clinical Trials**

ERIC O. ABOAGYE, A. R. PADHANI, AND PATRICIA M. PRICE

- I. Introduction 300
- II. PET 300
- III. Evaluation of Cancer Therapeutics with PET 302
- IV. MRI Assessment of Microvessel Function 311
- V. Conclusions 328
  - References 328

### **14 Devising Proof-of-Concept Strategies in Oncology Clinical Trials**

PAUL S. WISSEL

- I. Introduction 337
- II. Proof-of-Concept 338
- III. Elements of “The Concept” 339
- IV. Application of Surrogate End Points in Proof-of-Concept Decision Making 343
- V. Selected Statistical Considerations in Proof-of-Concept Studies 349
- VI. Pharmacodynamic Proof-of-Concept End Points 352
- VII. Pharmacokinetic Proof-of-Concept End Points 356
- VIII. Proceeding From Proof-of-Concept Directly to Phase III 359
- IX. Guidelines and Summary 360
  - Acknowledgements 361
  - References 361

### **15 Clinical Trial Designs for Cytostatic Agents and Agents Directed at Novel Molecular Targets**

EDWARD L. KORN, LARRY V. RUBINSTEIN, SALLY A. HUNSBERGER, JAMES M. PLUDA, ELIZABETH EISENHauer, AND SUSAN G. ARBUCK

- I. Introduction 366
- II. Phase I Dose-Finding Trials 366
- III. Preliminary Efficacy Trials 372
- IV. Definitive Randomized Efficacy Trials 376
- V. Conclusions 377
  - References 377

## **16 Cancer Gene Therapy Clinical Trials: From the Bench to the Clinic**

EVANTHIA GALANIS

- I. Regulatory Requirements and Good Manufacturing Practices for Gene Transfer Products 381
- II. Preclinical Development of Gene Therapy Vectors/Toxicology Testing 382
- III. Federal and Institutional Approval Processes for Clinical Gene Therapy Trials 383
- IV. Gene Therapy Clinical Trial Design 384
- V. Correlative End Points 386
- References 389

## **17 Molecular Targets for Radiosensitization**

ROGER OVE AND JAMES A. BONNER

- I. Introduction 391
- II. Growth Factor Receptors 394
- III. Ras 399
- IV. Modulation of p53 401
- V. DNA Damage Recognition and Repair 402
- VI. Other Promising Approaches 405
- VII. Conclusions 407
- VIII. Addendum 407
  - Addendum References 409
  - References 409

## **18 Patient Accrual to Clinical Trials**

SUSAN QUELLA

- I. Introduction 415
- II. Setting Up the Environment 415
  - References 425

**Index** 427

# CONTRIBUTORS

*Numbers in parentheses indicate the pages on which the authors' contributions begin.*

**Eric O. Aboagye** (299) PET Oncology Group, Department of Cancer Medicine, Imperial College School of Medicine, London, United Kingdom

**Alex A. Adjei** (249) Mayo Clinic and Foundation, Rochester, Minnesota

**Charles F. Albright** (83) Dupont Pharmaceuticals, Department of Cancer Research, Glenolden, Pennsylvania

**Margaret-Mary Ameyaw** (285) Departments of Medicine, Molecular Biology and Pharmacology, and Genetics, Washington University School of Medicine, The Siteman Cancer Center, St. Louis, Missouri

**Susan G. Arbuck** (365) Aventis Pharmaceuticals, Bridgewater, New Jersey; Current affiliation: Schering Plough Research Institute, Kenilworth, New Jersey

**James A. Bonner** (391) Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama

**John K. Buolamwini** (1) Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee

**Esteban Celis** (207) Mayo Clinic, Department of Immunology, Rochester, Minnesota

**Elizabeth Eisenhauer** (365) National Cancer Institute of Canada, Clinical Trials Group, Kingston, Ontario, Canada

**Evanthia Galanis** (379) Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, Minnesota

- Pearl S. Huang** (83) Dupont Pharmaceuticals, Department of Cancer Research, Glenolden, Pennsylvania
- Ying Huang** (223) Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York
- Sally A Hunsberger** (365) Biometric Research Branch, National Cancer Institute, Bethesda, Maryland
- James J. Kaminski (Deceased)** (93) Schering-Plough Research Institute, Kenilworth, New Jersey
- Lloyd R. Kelland** (233) St. George's Hospital Medical School, London, United Kingdom
- Edward L. Korn** (365) Biometric Research Branch, National Cancer Institute, Bethesda, Maryland
- W. Kusnezow** (37) Division of Functional Genome Analysis, German Cancer Research Center, Heidelberg, Germany
- Svetomir N. Markovic** (207) Mayo Clinic, Department of Hematology, Rochester, Minnesota
- Howard L. Mcleod** (285) Departments of Medicine, Molecular Biology and Pharmacology, and Genetics, Washington University School of Medicine, The Siteman Cancer Center, St. Louis, Missouri
- M. Nees** (37) Division of Molecular Diagnostics and Therapy, Department of Surgery, University of Heidelberg Germany
- Roger Ove** (391) Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama
- A.R. Padhani** (299) Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, United Kingdom
- Richard Pazdur** (263) Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland
- James M. Pluda** (365) Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland
- Robert Powers** (107) Department of Chemistry, University of Nebraska Lincoln, Lincoln, Nebraska
- Patricia M. Price** (299) PET Oncology Group, Department of Cancer Medicine, Imperial College School of Medicine, London, United Kingdom
- Susan Quella** (413) Mayo Clinic, Mayo Alliance for Clinical Trials (Mayo ACT), Rochester, Minnesota
- Larry V. Rubinstein** (365) Biometric Research Branch, National Cancer Institute, Bethesda, Maryland
- M. Saeed Sheikh** (223) Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York
- Marshall M. Siegel** (107) Discovery Analytical Chemistry, Wyeth Research, Pearl River, New York

- Hui Wang** (191) Department of Pharmacology and Toxicology, Cancer Pharmacology Laboratory, Comprehensive Cancer Center, and Gene Therapy Center, University of Alabama at Birmingham, Birmingham, Alabama
- Grant Williams** (263) Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland
- Paul S. Wissel** (337) Group Director, Clinical Development, GlaxoSmith Kline, Collegeville, Pennsylvania and Adjunct Associate Professor, University of Pennsylvania, Philadelphia, Pennsylvania
- C. D. Woodworth** (37) Department of Biology, Clarkson University, Potsdam, New York
- Ruiwen Zhang** (191) Department of Pharmacology and Toxicology, Cancer Pharmacology Laboratory, Comprehensive Cancer Center, and Gene Therapy Center, University of Alabama at Birmingham, Birmingham, Alabama

This Page Intentionally Left Blank